^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Rixathon (rituximab biosimilar) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
06/15/2017
Excerpt:
Rixathon in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia.
Secondary therapy:
Chemotherapy
